Mutated gene markers predict outcome for patients with AML.
Kaiser Permanente Oakland Medical Center, CA USA.
Deborah
D
McBride
D000970:Antineoplastic Agents / Q000627:therapeutic use; D005819:Genetic Markers; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D009154:Mutation; D011379:Prognosis; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics
D000970:Antineoplastic Agents; D005819:Genetic Markers; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3